With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

Eli Lilly has been making quite a bit of noise thanks to its work in diabetes and obesity. Investors turned on the company, ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.